Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cell Dev Biol
Main Authors: Fu, Yuyin, Peng, Yujia, Zhao, Shengyan, Mou, Jun, Zeng, Lishi, Jiang, Xiaohua, Yang, Chengli, Huang, Cheng, Li, Yuyan, Lu, Yin, Wu, Mengdan, Yang, Yanfang, Kong, Ting, Lai, Qinhuai, Wu, Yangping, Yao, Yuqin, Wang, Yuxi, Gou, Lantu, Yang, Jinliang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Cell and Developmental Biology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298272/
https://ncbi.nlm.nih.gov/pubmed/34307367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.689727
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados